Affimed N.V. (AFMDQ)

Market Cap	1.64K -100.0%
Revenue (ttm)	6.29M -72.9%
Net Income	-78.04M
EPS	-5.07
Shares Out	16.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,267
Open	0.0001
Previous Close	0.000001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	0.32
Analysts	Hold
Price Target	0.40 (+399,900.0%)
Earnings Date	Jun 8, 2026

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 76
• Stock Exchange: OTCMKTS
• Ticker Symbol: AFMDQ

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR